NCT06230055View on ClinicalTrials.gov

Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis

PHASE4RecruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

January 5, 2024

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2027

Conditions
HER2-negative Breast CancerLeptomeningeal Metastasis
Interventions
DEVICE

Ommaya reservoir

Intrathecal chemotherapy through Ommaya reservoir

DRUG

Systematic chemotherapy

Systematic chemotherapy: including capecitabine(1000mg/m2 bid, d1-14, q3w, po), gemcitabine(1000mg/m2, d1,8, q3w, ivgtt), vinorelbine(25mg/m2, d1,8, q3w, ivgtt), docetaxel(75mg/m2, d1, q3w, ivgtt),Nab-paclitaxel(125mg/m2, d1,8, q3w, ivgtt), iribrin(1.4mg/m2, d1,8, q3w, iv), DS8201(5.4mg/kg, d1, q3w), SG(10mg/kg, d1,8, q3w, ivgtt) or SKB264(5mg/kg, d1, q2w).

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER